Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Notes Payables (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Notes Payables for 13 consecutive years, with $755512.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Notes Payables fell 10.09% year-over-year to $755512.0, compared with a TTM value of $755512.0 through Dec 2025, down 10.09%, and an annual FY2025 reading of $755512.0, down 10.09% over the prior year.
  • Notes Payables was $755512.0 for Q4 2025 at Abvc Biopharma, up from $500000.0 in the prior quarter.
  • Across five years, Notes Payables topped out at $1.9 million in Q4 2022 and bottomed at $105300.0 in Q1 2021.
  • Average Notes Payables over 5 years is $1.1 million, with a median of $882750.0 recorded in 2023.
  • Peak annual rise in Notes Payables hit 1540.0% in 2021, while the deepest fall reached 57.58% in 2021.
  • Year by year, Notes Payables stood at $1.6 million in 2021, then increased by 15.47% to $1.9 million in 2022, then crashed by 52.51% to $899250.0 in 2023, then decreased by 6.56% to $840252.0 in 2024, then decreased by 10.09% to $755512.0 in 2025.
  • Business Quant data shows Notes Payables for ABVC at $755512.0 in Q4 2025, $500000.0 in Q3 2025, and $871951.0 in Q2 2025.